Coordinate alterations in the expression of BRCA1, BRCA2, p300, and Rad51 in response to genotoxic and other stresses in human prostate cancer cells

Prostate

Volumn 40, Issue 1, 1999, Pages 37-49

  Yuan, Renqi ^a   Fan, Saijun ^a   Wang, Ji An ^a   Meng, Qinghui ^a   Ma, Yongxian ^a   Schreiber, David ^a   Goldberg, Itzhak D ^a   Rosen, Eliot M ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Adriamycin (doxorubicin); BRCA1; BRCA2; Camptothecin; DNA damage; DU 145; p300; Prostate cancer; Rad51; Sodium selenite; Stress; Tsu Pr1; Ultraviolet

Indexed keywords

CAMPTOTHECIN; CHLORMETHINE; CYCLOHEXIMIDE; CYTOTOXIC AGENT; DOXORUBICIN; HEAT SHOCK PROTEIN; RECOMBINASE; SODIUM SELENITE;

APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL VIABILITY; CYTOTOXICITY; DNA REPAIR; GENE EXPRESSION; GENOTOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ULTRAVIOLET RADIATION;

BRCA2 PROTEIN; CELL SURVIVAL; DNA DAMAGE; DNA, NEOPLASM; DNA-BINDING PROTEINS; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BRCA1; HUMANS; MALE; MUTAGENS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROSTATIC NEOPLASMS; RAD51 RECOMBINASE; RNA, MESSENGER; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS;

EID: 0033564523     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19990615)40:1<37::AID-PROS5>3.0.CO;2-P     Document Type: Article

References (44)

1. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayanath P, Ward J, Tonin P, Narod S, Bristow P, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A, Skolnick MH. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
2. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994;343:692-695.
3. Friedman LS, Ostermeyer EA, Szabo CI, Dowd P, Lynch ED, Rowell SE, King MC. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet 1994;8:399-404.
4. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. The Breast Cancer Linkage Consortium. Am J Hum Genet 1995;56:265-271.
5. Langston AA, Stanford JL, Wicklund KG, Thompson JD, Blasej RG, Ostrander EA. Germ-line BRCA1 mutations in selected men with prostate cancer [letter]. Am J Hum Genet 1996;58:881-884.
6. Streuwing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdam SM, Timmerman MM, Brody LC, Tucker MA. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-1408.
7. Rosen EM, Fan S, Goldberg ID. BRCA1 and prostate cancer. Invited review. Cancer Invest 1999, in press.
8. Wooster R, Neuhausen SL, Mangion SL, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D, Fields P, Marshall G, Narod S, Lenoir GM, Lynch H, Feunteun J, Devilee P, Cornelisse CJ, Menko FH, Daly PA, Ormiston W, McManus R, Pye C, Lewis CM, Cannon-Albright LA, Peto J, Ponder BA, Skolnick MH, Easton DF, Goldgar DE, Stratton MR. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994;265:2088-2090.
9. Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, Merajver S, Thorlacius S, Offit K, Stoppa-Lyonnet D, Belanger C, Bell R, Berry S, Bogden R, Chen Q, Davis T, Dumont M, Frye C, Hattier T, Jammulapati S, Janecki T, Jiang P, Kehrer R, Leblanc J-F, Mitchell JT, McArthur-Morrison J, Nguyen K, Peng Y, Samson C, Schroeder M, Snyder SC, Steele L, Stringfellow M, Stroup C, Swedlund B, Swensen J, Teng D, Thomas A, Tran T, Tranchant M, Weaver-Feldhaus J, Wong AKC, Shizuya H, Eyfjord JE, Cannon-Albright L, Labrie F, Skolnick MH, Weber B, Kamb A, Goldgar DE. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 1996;12:333-337.
10. Chen Y, Farmer AA, Chen C-F, Jones DC, Chen P-L, Lee W-H. BRCA1 is a 200 kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner. Cancer Res 1996;56:3168-3172.
11. Chapman MS, Verma IM. Transcriptional activation by BRCA1. Nature 1996;382:678-679.
12. Monteiro AN, August A, Hanafusa H. Evidence for a transcription activation function of BRCA1 C-terminal region. Proc Natl Acad Sci USA 1996;93:13595-13599.
13. Milner J, Ponder B, Hughes-Davies L, Seltmann M, Kouzarides T. Transcriptional activation functions in BRCA2 [letter]. Nature 1997;386:772-773.
14. Holt JT, Thompson ME, Szabo C, Robinson-Benion C, Arteaga CL, King M-C, Jensen RA. Growth retardation and tumor inhibition by BRCA1. Nat Genet 1996;12:298-302.
15. Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 1995;9:444-450.
16. Rajan JV, Wang M, Marquis ST, Chodosh LA. Brca2 is coordinately regulated with Brca1 during proliferation and differentiation in mammalian epithelial cells. Proc Natl Acad Sci USA 1996;93:3078-3083.
17. Vaughn JP, Davis PL, Jarboe MD, Huper G, Evans AC, Weisman RW, Berchuck A, Inglehart JD, Futreal PA, Marks JR. BRCA1 expression is induced before DNA synthesis in both normal and rumor-derived breast cells. Cell Growth Differ 1996;7:711-715.
18. WAF1/CIP1. Nature 1997;389:187-190.
19. Wang H, Shao N, Ding OM, Qui J-Q, Reddy ESP, Rao VN. BRCA1 proteins are transported to the nucleus in the absence of serum and splice variants BRCA1a, BRCA1b are phosphoproteins that associate with E2F, cyclins, and cyclin-dependent kinases. Oncogene 1997;15:143-147.
20. Shao N, Chai YL, Shyam E, Reddy P, Rao VM. Induction of apoptosis by tumor suppressor protein BRCA1. Oncogene 1996; 13:1-7.
21. Rao VN, Shao N, Ahmad M, Reddy ES. Antisense RNA to putative tumor suppressor gene BRCA1 transforms mouse fibroblasts. Oncogene 1996;12:523-528.
22. Scully R, Chen J, Plug A, Xiao P, Weaver D, Feunteau J, Ashley T, Livingston D. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 1997;88:265-275.
23. Scully R, Chen J, Ochs RL, Keegan K, Hoekstra M, Feunteun J, Livingston DM. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell 1997;90:425-435.
24. Husain A, He G, Venkatraman ES, Spriggs DR. BRCA1 upregulation is associated with repair-mediated resistance to cisdiaminedichloroplatinum (II). Cancer Res 1998;58:1120-1130.
25. Sharan SK, Morimatsu M, Albrecht U, Lim DS, Regel E, Dinh Sands A, Eichele G, Hasty P, Bradley A. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 1997;386:804-810.
26. Tirkkonen M, Johannson O, Agnarsson BA, Olsson H, Ingvarsson S, Kahru R, Tanner N, Isola J, Barkardottir RB, Borg A, Kalloniemi O-P. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germline mutations. Cancer Res 1997;57:1222-1227.
27. Hakem R, de la Pomba JL, Sirard C, Mo R, Woo M, Hakem A, Wakeham A, Potter J, Reitmair A, Billia F, Firpo E, Hui CC, Roberts J, Rossant J, Mak TW. The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell 1996;85:1009-1023.
28. Wu LC, Wang ZW, Tsan JT, Spillman MA, Phung A, Zu XL, Yang MC, Hwang LY, Bowcock AM, Baer R. Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat Genet 1996;14:430-440.
29. Wang AKC, Pero R, Ormonde PA, Tavtigian SV, Bartel PL. Rad51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2. J Biol Chem 1997;272:31941-31944.
30. Baumann P, Benson FE, West SC. Human Rad51 protein promotes ATP-dependent homologous pairing and strand transfer reactions in vitro. Cell 1996;87:757-766.
31. Andres JL, Fan S, Turkel GJ, Wang J-A, Twu N-F, Yuan R-Q, Lamszus K, Goldberg ID, Rosen EM. Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents. Oncogene 1998;16:2229-2241.
32. Fan S, Twu N-F, Wang J-A, Yuan R-Q, Andres J, Goldberg ID, Rosen EM. Down-regulation of BRCA1 and BRCA2 in human ovarian cancer cells exposed to adriamycin and UV radiation. Int J Cancer 1998;77:600-609.
33. Fan S, Wang J-A, Yuan R-Q, Ma YX, Meng Q, Goldberg ID, Rosen EM. BRCA1 as a human prostate tumor suppressor: modulation of proliferation, damage responses, and expression of regulatory proteins. Oncogene 1998;16:3069-3083.
34. Connor F, Bertwistle D, Mee PJ, Ross GM, Swift S, Grigorieva E, Tybulewicz VLJ, Ashworth A. Tumorigenesis and a DNA repair defect in mice with truncating Brca2 mutation. Nat Genet 1997; 17:423-430.
35. Abbott DW, Freeman ML, Holt JT. Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J Natl Cancer Inst 1998;90:978-985.
36. Gowen LC, Avrutskaya AV, Latour AM, Koller BH, Leadon SA. BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science 1998;281:1009-1012.
37. el-Bayoumy K, Upadhyaya P, Chae YH, Sohn OS, Rao CV, Fiala E, Reddy BS. Chemoprevention of cancer by organoselenium compounds. J Cell Biochem [Suppl] 1995;22:92-100.
38. An WG, Kanekal M, Simon MC, Maltepe E, Blagosklonny MV, Neckers LM. Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature 1998;392:405-408.
39. Shikama N, Lyon L, La Thague NB. The p300/CBP family: integrating signals with transcription factors and chromatin. Trends Cell Biol 1997;7:230-236.
40. Somasundaram K, El-Deiry WS. Inhibition of p53-mediated transactivation and cell cycle arrest by E1A through its p300/ CBP-interacting region. Oncogene 1997;14:1047-1057.
41. Gerritsen ME, Williams AJ, Neish AS, Moore S, Shi Y, Collins T. CREB-binding protein/p300 are transcriptional coactivators of p65. Proc Natl Acad Sci USA 1997;94:2927-2932.
42. Hanstein B, Eckner R, DiRenzo J, Halachmi S, Liu M, Searcy B, Kurokawa R, Brown M. p300 is a component of an estrogen receptor coactivator complex. Proc Natl Acad Sci USA 1996;93: 11540-11545.
43. Sanchez-Prieto R, Lleonart M, Ramon y Cajal S. Lack of correlation between p53 protein level and sensitivity to DNA-damaging agents in keratinocytes carrying adenovirus E1a mutants. Oncogene 1995;11:675-682.
44. Samuelson AV, Lowe SW. Selective induction of p53 and chemosensitivity in RB-deficient cells by E1A mutants unable to bind the RB-related proteins. Proc Natl Acad Sci USA 1997;94: 12094-12099.